Prostate Cancer Survival Criteria in a Modern Interpretation

Abstract

According to the World Health Organization (WHO), the incidence of prostate cancer is constantly increasing worldwide and it is the third most common cancer in our country, after malignant tumors of the lung and stomach. Up to 40% of men between 60 and 70 years of age and 70% of men over 80 years of age have different stages of prostate cancer [1, 4].

Due to the specific features of the clinical course, the prostate tumor may not only not affect the patient's well-being for many years, but also not manifest itself in any way. The results of modern studies have shown that none of the currently used non-invasive methods can provide one hundred percent information about the presence of prostate cancer [2, 3].

In this regard, in order to improve the diagnosis and detection of the oncological process in the prostate at an early stage, the revolutionary HistoScan device was created and is successfully used [5]. This is a patented technology for differentiation, characterization and imaging of prostate tissue based on the analysis of ultrasound backscattering. This device can perform ultrasound examination of the prostate with a high degree of accuracy and identify areas of tissue suspicious for cancer. Thus, histoscan allows to suspect prostate cancer (stages T 1 - T 2). By displaying this information in the form of a 3D model and a map of the prostate, it is possible to determine the location and size of tumor tissue, obtain targeted tissue samples during a biopsy, reduce the number of tissue columns of biopsy material, as well as reduce the non-radical condition allows observation. cancer therapies, and furthermore, we are considering the possibility of targeting using histoscan mapping during focal therapy of prostate cancer.